华仁药业：全资子公司取得盐酸去氧肾上腺素注射液药品注册证书

Core Viewpoint - Hainan Pharmaceutical's subsidiary Anhui Hengxing Pharmaceutical has received approval from the National Medical Products Administration for the "Dexamethasone Hydrochloride Injection" registration certificate, which is expected to positively impact the company's development and product line [1] Group 1 - The approved drug is used to treat clinical hypotension caused by vasodilation during anesthesia [1] - The drug is classified as a Category B product under the national medical insurance scheme [1] - The projected domestic hospital sales for Dexamethasone Hydrochloride Injection in 2024 is 119 million yuan [1] Group 2 - The approval will enrich the company's product line and optimize its product structure [1] - The development is seen as a positive influence on the company's growth trajectory [1]